🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

How to write an introduction section for a medical research manuscript

Congratulations Shankar Siva. Super excited to have contributed to this important clinical trial, and looking forward to help roll renal #SBRT out as a standard management option for primary #RCC.

100% agree Daniel E Spratt Here's a popular #HIFU company's web posting... Vs data they reference vs other published data... (note their ref has no RP nor RT data). Yes failure def'n different for RP vs RT but drives salvage = more toxicity Maybe they need to hire new webmaster?

Great to see vHDRB going mainstream. Here is our data for 20Gy/2# boost - 94% efficacy, and low toxicity. Experimental arm in ongoing RCTs NINJA and PEACE 7. sciencedirect.com/science/articl…

Word of the Day: PSEUDOGLOT (neologism) - one who knows a few basic words in many languages and pretends to be a polyglot.

Congratulations Laura Dawson Radiation Medicine Program Princess Margaret Cancer Centre University Health Network Radiation Oncology and colleagues across Canada for publishing CCTG HE1 in The Lancet Oncology establishing single fraction RT as an effective palliative treatment for painful liver cancer. CCTG thelancet.com/journals/lanon…

#PACE A published in European Urology! SBRT vs Radical prostatectomy. Spread the word #SBRT should be discussed with eligible patients ⁦Dr Shaun Tolan⁩ Alison Tree 💙⁩ ⁦Clive Peedell⁩ Dr. Andrew Loblaw⁩ ⁦Prof Emma Hall⁩ Prof Joe O'Sullivan⁩ authors.elsevier.com/sd/article/S03…

Transdermal estradiol as a new option for testosterone lowering vs LHRHa : similar MFS & OS but different toxicity than LHRHa (less hot flashes, higher bone mineral density...) Open Qs: 1. efficacy vs antagonists 2. combination with other drugs (ARPI, PARPi) or RT #ESMO2024

I struggle with when to consider testosterone replacement for symptomatic men with controlled disease after ADT. After either six or 18 months of ADT, spontaneous recovery is rare after the two year mark, so some great data to inform shared decision making.

Tell me again why we can’t use renal SBRT in the UK?!? 100% local control is hard to beat. Masterclass by Shankar Siva #ASTRO24

#STORM trial examines elective nodal radiotherapy in treating #ProstateCancer recurrence. Piet Ost UGent joins Zach Klaassen Georgia Cancer Center to discuss, emphasizing that ENRT offers longer disease-free periods and lower pelvic recurrence rates compared to SBRT. #WatchNow >

Brachytherapy doses of radiotherapy delivered non-invasively for prostate cancer with 94.1% 5-year control and low rates of significant toxicity. Now being investigated in randomised trials such as Trans Tasman Radiation Oncology Group NINJA and GETUG PEACE 7.

Delighted to share the results of #PACE B trial, published in NEJM today 5 fraction SBRT is non inferior to CRT! nejm.org/media/doi/full… Alison Tree 💙 Follow us on Bluesky @ICR-CTSU Prof Emma Hall The Royal Marsden NHS Foundation Trust Dr. Andrew Loblaw Clive Peedell ST Prof Joe O'Sullivan Prof Suneil Jain

ProPSMA - the gift that keeps on giving! Great to be part of such an impactful collaboration.

Thanks for sharing! The ASTRO 2025 AM in San Francisco (Sep 27-Oct 1) will have a 3 hr symposium on Sun featuring RT for non-malignant disease, including cardiac. Your fellow Aussie, Prof Jarad Martin, is helping put it together. See you this Fall, if not sooner!

Today our 2025 ANZUP Idea Generation Workshops continue with #ProstateCancer today led by #ProfLisaHorvath & Prof Jarad Martin with over 10 concepts being presented #ANZUPconcepts PCFA Cancer Australia Ian Davis (Bluesky @profiand)